Serving hundreds of leading biopharmaceutical companies globally:

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,034,877

« Back to Dashboard

Which drugs does patent 10,034,877 protect, and when does it expire?

Patent 10,034,877 protects TRADJENTA and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 10,034,877

Title:	Treatment for diabetes in patients inappropriate for metformin therapy
Abstract:	The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
Inventor(s):	Dugi; Klaus (London, GB), Graefe-Mody; Eva Ulrike (Ingelheim am Rhein, DE), Harper; Ruth (Reading, GB), Woerle; Hans-Juergen (Munich, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	15/287,228
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 10,034,877
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,034,877

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 10,034,877

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072920	➤ Sign Up
Australia	2009279085	➤ Sign Up
Canada	2732803	➤ Sign Up
China	102105145	➤ Sign Up
China	103550219	➤ Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.